Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ increased its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 428.7% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 476,421 shares of the company’s stock after acquiring an additional 386,306 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Elanco Animal Health were worth $16,527,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Tompkins Financial Corp acquired a new stake in shares of Elanco Animal Health in the first quarter valued at $27,000. Captrust Financial Advisors acquired a new stake in shares of Elanco Animal Health in the first quarter valued at $28,000. Fifth Third Bancorp lifted its holdings in shares of Elanco Animal Health by 699.3% during the second quarter. Fifth Third Bancorp now owns 1,143 shares of the company’s stock valued at $40,000 after purchasing an additional 1,000 shares during the last quarter. Quadrant Capital Group LLC lifted its holdings in shares of Elanco Animal Health by 216.6% during the first quarter. Quadrant Capital Group LLC now owns 1,200 shares of the company’s stock valued at $35,000 after purchasing an additional 821 shares during the last quarter. Finally, Proequities Inc. lifted its holdings in shares of Elanco Animal Health by 37.8% during the first quarter. Proequities Inc. now owns 1,239 shares of the company’s stock valued at $36,000 after purchasing an additional 340 shares during the last quarter. Institutional investors and hedge funds own 99.58% of the company’s stock.

Shares of Elanco Animal Health stock opened at $32.92 on Wednesday. The stock has a 50-day moving average price of $33.79 and a 200 day moving average price of $33.05. The company has a market cap of $15.57 billion, a P/E ratio of -21.95, a P/E/G ratio of 0.66 and a beta of 0.83. The company has a current ratio of 1.72, a quick ratio of 1.00 and a debt-to-equity ratio of 0.69. Elanco Animal Health Incorporated has a 1 year low of $25.76 and a 1 year high of $37.49.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Sunday, August 8th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.02. Elanco Animal Health had a positive return on equity of 5.24% and a negative net margin of 16.02%. The firm had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same period in the prior year, the business earned ($0.09) EPS. The business’s revenue for the quarter was up 118.3% on a year-over-year basis. On average, equities analysts forecast that Elanco Animal Health Incorporated will post 1.01 earnings per share for the current fiscal year.

Several brokerages have recently commented on ELAN. Cleveland Research raised Elanco Animal Health from an “underperform” rating to a “neutral” rating in a report on Tuesday, June 15th. Credit Suisse Group began coverage on Elanco Animal Health in a report on Thursday, August 5th. They set an “outperform” rating and a $38.00 target price for the company. Finally, Zacks Investment Research downgraded Elanco Animal Health from a “buy” rating to a “hold” rating in a report on Friday, June 18th. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Elanco Animal Health has a consensus rating of “Buy” and a consensus target price of $37.75.

In other news, major shareholder Elanco Animal Health Inc bought 45,508,938 shares of the company’s stock in a transaction on Friday, August 27th. The shares were bought at an average cost of $9.25 per share, with a total value of $420,957,676.50. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Jeffrey N. Simmons acquired 16,850 shares of the stock in a transaction dated Wednesday, August 11th. The shares were bought at an average cost of $29.70 per share, for a total transaction of $500,445.00. Following the acquisition, the chief executive officer now owns 568,577 shares in the company, valued at approximately $16,886,736.90. The disclosure for this purchase can be found here. Over the last ninety days, insiders acquired 45,528,788 shares of company stock worth $421,545,062. Insiders own 6.11% of the company’s stock.

Elanco Animal Health Profile

Elanco Animal Health, Inc engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine.

Featured Article: What is a conference call?

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.